Literature DB >> 10388026

Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.

.   

Abstract

This review compares the tolerability profiles of the three currently available nonsteroidal antiandrogens, flutamide, bicalutamide and nilutamide. Pharmacological effects associated with blockade of the androgen receptor are frequent with all three drugs. Gynecomastia and breast pain are seen more frequently during antiandrogen monotherapy than during combination with medical or surgical castration or castration alone, and the reverse is true for hot flashes, which are a side effect of castration. Gastrointestinal symptoms are also common to all three drugs, but diarrhea occurs more frequently in flutamide studies than in bicalutamide or nilutamide studies. Hepatotoxicity has been seen with all three antiandrogens, but acute, reversible hepatitis and fatal fulminant hepatitis have also been reported with both nilutamide and flutamide. All three drugs have been associated with asymptomatic elevations in aminotransferases and may reduce hemoglobin levels. Adverse events that have been reported with nilutamide include interstitial pneumonitis, delayed adaptation to darkness after exposure to bright light and alcohol intolerance. To date, bicalutamide appears to have some advantage over flutamide and nilutamide in terms of tolerability.

Entities:  

Year:  1997        PMID: 10388026

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  23 in total

1.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

2.  Fulminant hepatic failure due to nilutamide hepatotoxicity.

Authors:  Shehzad N Merwat; Wareef Kabbani; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2008-08-08       Impact factor: 3.199

Review 3.  An update on enzalutamide in the treatment of prostate cancer.

Authors:  Axel S Merseburger; Gabriel P Haas; Christoph-A von Klot
Journal:  Ther Adv Urol       Date:  2015-02

Review 4.  Endocrine and adrenergic pharmacological intervention in diseases of the prostate.

Authors:  A Rane
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

5.  Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer.

Authors:  Y Yang; R Chen; T Sun; L Zhao; F Liu; S Ren; H Wang; X Lu; X Gao; C Xu; Y Sun
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

6.  Bicalutamide adjuvant to radical prostatectomy.

Authors:  William A See
Journal:  Rev Urol       Date:  2004

Review 7.  Antiandrogens in prostate cancer.

Authors:  P Reid; P Kantoff; W Oh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.

Authors:  A A Goldberg; V I Titorenko; A Beach; K Abdelbaqi; S Safe; J T Sanderson
Journal:  Invest New Drugs       Date:  2013-05-25       Impact factor: 3.850

9.  Management options for gynaecomastia and breast pain associated with nonsteroidal antiandrogen therapy : case report series.

Authors:  I Leibovitch; D Gillatt; P Hopwood; P Iversen; R E Mansel; D McLeod; R Vela-Navarrete; P Richaud; W See; C Tyrrell; M Wirth
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Atypical onset of bicalutamide-induced liver injury.

Authors:  Gee Young Yun; Seok Hyun Kim; Seok Won Kim; Jong Seok Joo; Ju Seok Kim; Eaum Seok Lee; Byung Seok Lee; Sun Hyoung Kang; Hee Seok Moon; Jae Kyu Sung; Heon Young Lee; Kyung Hee Kim
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.